| Entry |
|
|---|
| Name |
Lumateperone (USAN/INN) |
|---|
| Formula |
C24H28FN3O
|
|---|
| Exact mass |
393.2216
|
|---|
| Mol weight |
393.50
|
|---|
| Structure |
|
|---|
| Remark |
| Product (DG02937): | D11170<US> |
|
|---|
| Efficacy |
Antipsychotic |
|---|
| Comment |
Treatment of schizophrenia, bipolar disorder and behavioral and sleep disturbances
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AD Butyrophenone derivatives
N05AD10 Lumateperone
D11169 Lumateperone (USAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D11169 Lumateperone (USAN/INN)
Serotonin
HTR2A
D11169 Lumateperone (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 29
1 C8x C 13.1254 -16.5465
2 C8y C 13.1254 -17.9428
3 C8x C 14.3122 -18.6410
4 C8x C 15.5689 -17.9428
5 C8y C 15.5689 -16.5465
6 C8x C 14.3122 -15.8484
7 C5a C 16.7558 -15.8484
8 C1b C 18.0125 -16.5465
9 C1b C 19.1993 -15.8484
10 C1b C 20.3862 -16.5465
11 N1y N 21.5731 -15.8484
12 C1x C 22.8298 -16.5465
13 C1y C 24.0166 -15.8484
14 C1y C 24.0166 -14.4521
15 C1x C 22.8298 -13.7539
16 C1x C 21.5731 -14.4521
17 X F 11.9385 -18.6410
18 O5a O 16.7558 -14.4521
19 C8y C 25.3446 -16.2799
20 C8y C 26.1654 -15.1502
21 N1y N 25.3446 -14.0206
22 C8y C 27.5577 -15.1439
23 N1y N 28.1971 -13.9349
24 C1x C 27.4464 -12.6653
25 C1x C 26.1241 -12.6716
26 C8x C 26.0541 -17.5588
27 C8x C 27.4464 -17.5652
28 C8x C 28.1971 -16.3655
29 C1a C 29.5368 -13.8359
BOND 33
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 13 14 1
15 14 15 1
16 15 16 1
17 11 16 1
18 2 17 1
19 7 18 2
20 13 19 1
21 19 20 1
22 20 21 1
23 14 21 1
24 20 22 2
25 22 23 1
26 23 24 1
27 24 25 1
28 21 25 1
29 19 26 2
30 26 27 1
31 27 28 2
32 28 22 1
33 23 29 1
|
|---|
